These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35786181)

  • 1. Machine Learning Assisted Discovery of Novel p38α Inhibitors from Natural Products.
    Shen T; Tao Y; Liu B; Kong D; Zhang R; Xiao W
    Comb Chem High Throughput Screen; 2023; 26(6):1214-1223. PubMed ID: 35786181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
    Lan P; Huang ZJ; Sun JR; Chen WM
    Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-stage virtual screening of natural products against p38α mitogen-activated protein kinase: predictive modeling by machine learning, docking study and molecular dynamics simulation.
    Yang R; Zha X; Gao X; Wang K; Cheng B; Yan B
    Heliyon; 2022 Sep; 8(9):e10495. PubMed ID: 36105464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovering novel P38α inhibitors for the treatment of prostate cancer through virtual screening methods.
    Li K; Li Z; Tao Y; Wang Q; Lai Y; Wu W; Peng S; Guo Z; Huang H
    Future Med Chem; 2019 Dec; 11(24):3125-3137. PubMed ID: 31838901
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same.
    Sahu V; Nigam L; Agnihotri V; Gupta A; Shekhar S; Subbarao N; Bhaskar S; Dey S
    Cancer Res Treat; 2019 Jan; 51(1):313-325. PubMed ID: 29747487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
    Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
    J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel ULK1 inhibitors through machine learning-guided virtual screening and biological evaluation.
    Kong MM; Wei T; Liu B; Xi ZX; Ding JT; Liu X; Li K; Qin TL; Qian ZY; Wu WC; Wu JZ; Li WL
    Future Med Chem; 2024; 16(18):1821-1837. PubMed ID: 39145469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dibenzepinones, dibenzoxepines and benzosuberones based p38α MAP kinase inhibitors: Their pharmacophore modelling, 3D-QSAR and docking studies.
    Khan MF; Verma G; Alam P; Akhter M; Bakht MA; Hasan SM; Shaquiquzzaman M; Alam MM
    Comput Biol Med; 2019 Jul; 110():175-185. PubMed ID: 31173941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of naphthyl-N-acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity.
    Freitas RHCN; Cordeiro NM; Carvalho PR; Alves MA; Guedes IA; Valerio TS; Dardenne LE; Lima LM; Barreiro EJ; Fernandes PD; Fraga CAM
    Chem Biol Drug Des; 2018 Feb; 91(2):391-397. PubMed ID: 28815968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future prospects of p38α/MAPK14 kinase and its inhibitors.
    Madkour MM; Anbar HS; El-Gamal MI
    Eur J Med Chem; 2021 Mar; 213():113216. PubMed ID: 33524689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNS-Active p38α MAPK Inhibitors for the Management of Neuroinflammatory Diseases: Medicinal Chemical Properties and Therapeutic Capabilities.
    Valipour M; Mohammadi M; Valipour H
    Mol Neurobiol; 2024 Jul; 61(7):3911-3933. PubMed ID: 38041716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a potent p38α/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies.
    El-Gamal MI; Anbar HS; Tarazi H; Oh CH
    Eur J Med Chem; 2019 Dec; 183():111684. PubMed ID: 31520926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
    Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
    J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.